[两例接受XELOXIRI作为局部晚期直肠癌新辅助化疗的病例的病理完全缓解情况]
[pCR Achievement in Two Cases Treated with XELOXIRI as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer].
作者信息
Ozato Yuki, Tei Mitsuyoshi, Sueda Toshinori, Matsumura Tae, Furukawa Haruna, Koga Chikato, Wakasugi Masaki, Miyagaki Hiromichi, Kawabata Ryohei, Shimizu Junzo, Miwa Hideaki, Hasegawa Junichi
机构信息
Dept. of Surgery, Osaka Rosai Hospital.
出版信息
Gan To Kagaku Ryoho. 2020 Mar;47(3):484-486.
BACKGROUND
Neoadjuvant chemotherapy is designed to prevent disease recurrence, particularly distant recurrence, and to improve overall patient survival. We present 2 cases where pathological complete response(pCR)was obtained after administering XELOXIRI as neoadjuvant chemotherapy for locally advanced rectal cancer. Case 1: The patient was a 63-year-old man diagnosed with rectal cancer(Ra, cT4aN1M0, cStage Ⅲa)and treated with 6 courses of XELOXIRI as neoadjuvant chemotherapy. After systemic chemotherapy, he underwent laparoscopy-assisted low anterior resection and showed a pCR. Case 2: The patient was a 56-year-old man diagnosed with rectal cancer(Rb, cT3N3M0, cStage Ⅲb)and treated with 6 couses of XELOXIRI as neoadjuvant chemotherapy. After systemic chemotherapy, he underwent low anterior resection and showed a pCR.
CONCLUSION
We present 2 cases treated with XELOXIRI as neoadjuvant chemotherapy for locally advanced rectal cancer where pCRwas achieved.
背景
新辅助化疗旨在预防疾病复发，尤其是远处复发，并提高患者的总体生存率。我们介绍2例局部晚期直肠癌患者，在接受XELOXIRI新辅助化疗后获得了病理完全缓解（pCR）。病例1：患者为一名63岁男性，诊断为直肠癌（Ra，cT4aN1M0，cⅢa期），接受6个疗程的XELOXIRI新辅助化疗。全身化疗后，他接受了腹腔镜辅助低位前切除术，显示为pCR。病例2：患者为一名56岁男性，诊断为直肠癌（Rb，cT3N3M0，cⅢb期），接受6个疗程的XELOXIRI新辅助化疗。全身化疗后，他接受了低位前切除术，显示为pCR。
结论
我们介绍了2例局部晚期直肠癌患者接受XELOXIRI新辅助化疗并实现pCR的病例。
Zotero 插件